BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink tough pancreatic tumors before surgery
Disease control Recruiting nowThis study is testing a specific combination of four chemotherapy drugs given to patients before surgery for a type of pancreatic cancer that is difficult to remove. The goal is to see if shrinking the tumor first makes surgery more successful and lowers the chance of the cancer …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Genetic clues to target pancreatic cancer faster
Disease control Recruiting nowThis study aims to see if quickly analyzing the genetic makeup of a pancreatic tumor can help doctors choose the most effective treatment. It will enroll 200 adults with pancreatic cancer that has not spread to distant organs. Participants will receive standard chemotherapy and p…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Breakthrough radiation technique offers hope for tough pancreatic tumors
Disease control Recruiting nowThis study is testing a new radiation therapy approach called PULSAR combined with standard chemotherapy for people with advanced pancreatic cancer. The PULSAR method delivers radiation in spaced-out 'pulses' over several weeks, which may reduce side effects while better targetin…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Scientists probe six drugs in race to outsmart pancreatic cancer
Knowledge-focused Recruiting nowThis early study aims to understand how six different investigational drugs affect the biology of pancreatic cancer tumors. It will enroll about 90 adults with various stages of pancreatic cancer. Participants take one of the drugs for about 10 days before a scheduled biopsy or s…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC